Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), for a more advanced version of ...

Let's look at five pharma and drug companies, MRK PFE, LLY, AMGN and BMY, which are scheduled to release their fourth-quarter ...

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...

Merck shares are down more than 20% over the past 12 months after trouble with sales of its Gardasil vaccine in China ...

Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...

indicates confidence in the drug’s efficacy but still requires further data presentation for comprehensive evaluation. While the trial’s early success and Merck’s increased sales guidance ...